Cromolyn sodium in XXXX .

@entity1 @entity2194 @entity6358 @entity2715 @entity27179 @entity56 @entity9992 @entity7232
A formulation of 2% @entity9992 (CS) ophthalmic solution without the preservative, @entity27179 , was compared with placebo in 58 @entity1 with @entity56 . Selection was based on history and positive skin tests. Neither immunotherapy nor use of antihistamines was allowed. This study was double-blinded and stratified by RAST scores to assure comparable groups. Either CS or placebo was used six times daily. @entity1 were observed weekly for 5 weeks during the peak of the fall weed-pollen exposure. Nasal symptoms were treated as required with @entity2715 nasal spray, and uncontrolled ocular symptoms were treated with @entity7232 and @entity6358 solution. Nasal and ocular symptoms were recorded. There was a significant @entity2194 in the group receiving CS ophthalmic solution (p less than 0.02) during weeks 2, 4, and 5. There was a trend for nasal symptoms and the requirement for nasal @entity2715 to be less in @entity1 receiving CS.
